Vaccination In Pregnancy Gene Signature: VIP Signature Study

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

30 participants

Study Classification

OBSERVATIONAL

Study Start Date

2017-09-07

Study Completion Date

2018-03-21

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

A study investigating gene expression profiles in pregnant women in response to a pertussis containing vaccination in pregnancy.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Optimising the Timing of Whooping Cough Immunisation in MUMs

NCT03908164

UNKNOWN PHASE4

Study Evaluating the Safety of a Recombinant Acellular Pertussis Vaccine in Pregnant Women

NCT06888076

Pertussis Vaccines Pertussis (Whooping Cough)

ACTIVE_NOT_RECRUITING

Maternal Determinants of Infant Immunity to Pertussis

NCT05856396

Vaccination; Infection Maternal-Fetal Relations Pertussis +1 more

COMPLETED PHASE4

Pertussis (Tdap) Vaccination in Pregnancy

NCT01698346

Pertussis Pregnancy

COMPLETED PHASE4

A Trial Comparing Two Pertussis-containing Vaccines in Pregnancy and Vaccine Responses in UK Mothers and Their Infants

NCT02145624

Responses to Infant Immunisations

COMPLETED PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Vaccinations are a vital part of ensuring population health, but there is a continued need for new and improved vaccines to be developed and this process of design and development can be both slow and expensive. Vaccination in pregnancy against pathogens such as pertussis, influenza and tetanus is a routine part of antenatal care in many countries. The principle behind this approach is that through vaccination the amount of disease specific antibody is increased in the woman and there is therefore an increase in transplacental transfer to the fetus providing protection for infants after birth. In the UK vaccination against pertussis is recommended from 16 weeks gestation and against influenza at any gestation within the influenza season. There is evidence that pertussis vaccination in pregnancy is highly effective against pertussis in infants too young to be protected by the routine infant immunisation programme (Amirthalingam G et al, 2014, Dabrera G et al, 2015). There is also evidence that this is a safe strategy in pregnancy to protect newborn infants (Donegan K et al, 2014) with no evidence of adverse clinical outcomes for mother or infant.

The BioVacSafe project has been designed to develop techniques which can be used to understand more about biomarkers of safety in individuals' response to vaccines. This will improve our understanding of how reactogenicity can be identified earlier, how adverse reactions can be identified and classified and how individuals interact with vaccines, specifically in conditions of health and disease. Since the start of the BioVacSafe project the importance of vaccination in pregnancy has become better understood and it has become important to include pregnant women as participants in this project. Pregnancy is a time of altered immunity and it may be that there are differences in gene signatures following vaccination in pregnant women compared with non-pregnant women. Insights into this could be extremely important in the development of new vaccines for this population.

Safety of vaccination in pregnancy is of primary importance to pregnant women and their partners, clinical trials investigators, ethics committees, vaccine manufacturers and regulators. Determining specific genetic signatures following vaccination may accelerate vaccine development by predicting possible adverse events early in the development process.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Pregnancy Related Vaccination

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

All women

Women who are between 16-32 weeks gestation and who have not previously received a pertussis vaccination in pregnancy.

Vaccination with a pertussis containing vaccine

Intervention Type BIOLOGICAL

Vaccination with a pertussis containing vaccine

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Vaccination with a pertussis containing vaccine

Intervention Type BIOLOGICAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Pregnant at a gestation of 16-32 weeks
* No contraindications to vaccination according to the green book
* No known immunodeficiency
* Able to understand the details of the study and willing to provide informed consent